

UCLA JONSSON COMPREHENSIVE CANCER CENTER

Medical Oncology — Breast Oncology
2825 Santa Monica Boulevard, Suite 200, Santa Monica CA 90404
Phone: 310-555-0600 | Fax: 310-555-0601
NPI: 1345678921

February 01, 2026

Blue Cross Blue Shield
Federal Employee Program
Prior Authorization Department
Medical Review Unit

RE: Letter of Medical Necessity

Patient Name:	Catherine Park
Date of Birth:	1967-12-05
Member ID:	FEP891234567
Group Number:	FEP-STANDARD-2024
Medication Requested:	Palbociclib (Ibrance)
Diagnosis:	Malignant neoplasm of unspecified site of left female breast (C50.912)

To Whom It May Concern:

I am writing on behalf of my patient, Catherine Park, to document the medical necessity of Palbociclib (Ibrance) for the treatment of Malignant neoplasm of unspecified site of left female breast. This letter provides clinical documentation supporting the need for this medication and demonstrates that my patient meets the coverage criteria for this therapy.

CLINICAL HISTORY AND DIAGNOSIS

58-year-old postmenopausal Korean American female presenting with back pain and found to have de novo metastatic breast cancer. Left breast mass detected on screening mammogram December 2025. Core biopsy confirmed invasive ductal carcinoma, Grade 2, ER+/PR+/HER2-. Staging CT and bone scan revealed osseous metastases in T8, T10, and left iliac crest. No visceral metastases. ECOG 0. Recommended first-line therapy: palbociclib + letrozole (aromatase inhibitor). No prior systemic therapy for breast cancer. No prior endocrine therapy.

CURRENT DISEASE ACTIVITY

Most recent assessment (2026-01-20):

- Stage: IV (metastatic)
- Ecog Performance Status: 0
- Ecog Interpretation: Fully active, able to carry on all pre-disease activities
- Metastatic Sites: ['Bone (thoracic spine T8, T10; left iliac crest)']
- Disease Status: newly_diagnosed_metastatic

MEDICAL NECESSITY SUMMARY

Based on the clinical evidence presented, Palbociclib (Ibrance) is medically necessary for Catherine Park. The patient has a confirmed diagnosis of Malignant neoplasm of unspecified site of left female breast (ICD-10: C50.912). Key criteria met: Advanced/metastatic breast cancer confirmed — Stage IV with bone metastases; ER 95%, PR 80% — strongly HR-positive; HER2 IHC 1+, FISH not amplified — HER2-negative; Patient is 58 years old (≥ 18). I respectfully request approval of this prior authorization.

Please contact my office if you require any additional clinical information.

Sincerely,

Dr. Lisa Chang, MD, FASCO

Medical Oncology — Breast Oncology

NPI: 1345678921

Date: 02/01/2026